Drug – bio-affecting and body treating compositions – Enzyme or coenzyme containing
Reexamination Certificate
2007-01-02
2007-01-02
Saucier, Sandra E. (Department: 1651)
Drug, bio-affecting and body treating compositions
Enzyme or coenzyme containing
Reexamination Certificate
active
10497683
ABSTRACT:
Uses of aldose 1-epimerase (SEQ ID NO:3) from body fluids or body tissues in human and veterinary medicine as a marker peptide for diagnosis, for prognosis of the course and for monitoring of the course of inflammations and infections and/or as a target for therapeutically influencing the course of inflammations and/or infections.
REFERENCES:
patent: 5639617 (1997-06-01), Bohuon
patent: 6756483 (2004-06-01), Bergmann et al.
patent: 198 47 690 (2000-04-01), None
patent: 101 19 804 (2002-10-01), None
patent: 101 30 985 (2003-01-01), None
patent: 101 31 922 (2003-01-01), None
patent: WO 00/22439 (2000-04-01), None
patent: WO02090521 (2002-11-01), None
Naslund B. et al. Glucose determination in samples taken by microdialysis by peroxidase-catalyzed luminol chemiluminescence. Anal. Biochem. Jan. 1991; 192(1): 237-42.
Meisner M. et al. “Comparision of procalcitonin (PCT) and C-reactive protein (CRP) plasma concentrations at different SOFA scores during the course of sepsis and MODS”, Crit. Care 1999, 3: 45-50, entire document.
Menzel C. et al, “Development of biosensors based . . . process monitoring. part I. Development of the biosensors and their characterization”, Analytica Chimica Acta, 1995, 317: 259-264. entire document.
A. Beishuizen et al., “Endogenous Mediators in Sepsis and Septic Shock”,Advances in Clinical Chemistry, vol. 33 (1999) 55-131.
C. Gabay et al., “Acute Phase Proteins and Other Systemic Responses to Inflammation”,The New England Journal of Medicine, vol. 340, No. 6, (1999) 448-454.
K. Reinhart et al., “Sepsis and septischer Schock” [Sepsis and septic shock], in:Intensivmedizin, Georg Thieme Verlag, Stuttgart (2001) 756-760.
M. Assicot et al., “High serum proclacitonin concentrations in patients with sepsis and infection”,The Lancet, vol. 341, No. 8844 (1993) 515-518.
W. Karzai et al., “Procalcitonin—A New Indicator of the Systemic Response to Severe Infection”,Infection, vol. 25 (1997) 329-334.
M. Oczenski et al., “Procalcitonin: a new parameter for the diagnosis of bacterial infection in the peri-operative period”,European Journal of Anaesthesiologyvol. 15 (1998) 202-209.
H. Redl et al., “Procalcitonin release patterns in a baboon model of trauma and sepsis: Relationship to cytokines and neopterin”Crit Care Medvol. 28, No. 11 (2000) 3659-3663.
H. Redl et al., “Non-Human Primate Models of Sepsis”Sepsis, vol. 2 (1998) 243-253.
E.A. Panacek, “Anti-TNF strategies”Journal für Anästhesie und Intensivbehandlung, No. 2 (2001) 4-5.
T. Calandra et al., “Protection from septic shock by neutralization of macrophage migration inhibitory factor”Nature Medicine, vol. 6, No. 2 (2000) 164-170.
Ghillani et al., “Monoclonal antipeptide antibodies as tools to dissect closely related gene products”The Journal of Immunology, vol. 141, No. 9 (1988) 3156-3163.
Ghillani et al., “Identification and Measurement of Calcitonin Precursors in Serum of Patients with Malignant Diseases”Cancer Research, vol. 49, No. 23 (1989) 6845-6851.
J. Klose, “Fractionated Extraction of Total Tissue Proteins from Mouse and Human for 2-D electrophoresis”Methods in Molecular Biology, vol. 112: 2-D Proteome Analysis Protocols, Humana Press Inc., Totowa, NJ.
J. Klose et al., “Two-dimensional electrophoresis of proteins: An updated protocol and implications for a functional analysis of the genome”Electrophoresis16 (1995) 1034-1059.
V. Neuhoff et al., “Improved staining of proteins in polyacrylamide gels including isoelectric focusing gels with clear background at nanogram sensitivity using Coomassie Brilliant Blue G-250 and R-250”Electrophoresis9 (1988) 255-262.
A. Otto et al., “Identification of human myocardial proteins separated by two-dimensional electrophoresis using an effective sample preparation for mass spectrometry”,Electrophoresis17 (1996) 1643-1650.
G. Neubauer et al., “Mass spectrometry and EST-database searching allows characterization of the multi-protein spliceosome complex”Nature Genetics, vol. 20 (1998) 46-50.
J. Lingner et al., “Reverse Transcriptase Motifs in the Catalytic Subunit of Telomerase”,Science, vol. 276 (1997) 561-567.
M. Mann et al., “Use of mass spectrometry-derived data to annotate nucleotide and protein sequence databases” TRENDS in Biochemical Sciences, vol. 26, No. 1 (2001) 54-61.
Weibel “A Coupled Enzyme Assay for Aldose-1-epimerase EC-5.1.3.3”Analytical Biochemistry70:2 (1976) 489-494.
Strausberg “Hypothetical 37,8 kDA Protein” EMBL Database, Database Accession No. Q96C23 (Dec. 2001).
Bergmann Andreas
Struck Joachim
Ühlein Monika
B.R.A.H.M.S Aktiengesellschaft
Mayer Brown Rowe & Maw
Saucier Sandra E.
Sharer Paul L.
Singh Satyendra K.
LandOfFree
Uses of aldose-1-epimerase (mutarotase) for diagnosis and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Uses of aldose-1-epimerase (mutarotase) for diagnosis and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Uses of aldose-1-epimerase (mutarotase) for diagnosis and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3782056